In Study CK-301-101, the primary efficacy endpoint was objective response rate (complete + partial response, by independent central review), which was 47% (n = 15) in 32 mCSCC patients evaluable for response, including 3 complete responses and 12 partial responses. The results from the study were presented at the ESMO Congress.
In this Original Investigation from JAMA Oncology, the authors attempt to discover whether increased coffee consumption is associated with improved survival in patients with advanced or metastatic colorectal cancer. Overall survival (OS) and progression-free survival (PFS) were the main outcomes and measures, and both decaffeinated and caffeinated coffee were studied.
The NCI sponsors and funds the consortium, a multidisciplinary cooperative research organization devoted to the study of correlative tumor biology and new therapies for children with primary central nervous system tumors. New members are chosen through a competitive process based on several characteristics, including clinical trial infrastructure and expertise in basic and translational science.
In this study from the Journal of Clinical Oncology, the authors attempted to characterize the cancer-associated risk factors for COVID-19 adverse outcomes. Their hypothesis was that cytotoxic chemotherapy administered within 35 days of a COVID-19 diagnosis is associated with an increased hazard ratio (HR) of severe or critical COVID-19. Were they right?
Older adults with acute myeloid leukemia (AML) represent a vulnerable population in whom disease-based and clinical risk factors, patient goals, prognosis, and practitioner- and patient-perceived treatment risks and benefits influence treatment recommendations. Discover what the American Society of Hematology (ASH) recommends for your older adult AML patients.
Data from the 1,459 patients who were African American, Hispanic, Native American, Pacific Islander, or Asian highlighted the need for increased surveillance for cutaneous toxicity in patients with darker pigmented skin. irCAEs were assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v5.0.
The study looked at cancer survivors aged 65 or older from the SEER-Medicare database; survivors were diagnosed with cancer between 2000 and 2012. Claims from 2007 to 2013 were used to estimate costs by cancer site, phases of care, and stage at diagnosis.
Published in JCO Clinical Practice and developed by a working group of 7 experts in oncology pharmacy practice, the guidelines outline 26 recommendations covering the use of anticancer medications, from proper staff hygiene and safety to how to conduct clinical trials.
In addition to reducing pack-years history of smoking, the recommendation calls for annual screening for lung cancer at age 50 years instead of age 55 years, an update of the U.S. Preventive Services Task Force (USPSTF) guidance on lung cancer screening issued 7 years ago.
In this podcast, Dr. Jennifer Caudle speaks with Drs. Kathryn Ruddy and Joerg Herrmann from the cardio-oncology clinic at the Mayo Clinic to talk about the field that’s devoted to improving cardiovascular health both during and after cancer therapy.